ArticleCancer medicine2025
The Prognostic Value of Nutritional and Immune Indices for Stage IB Non-Small Cell Lung Cancer Patients: Insights From a Retrospective Cohort Study.
Article in Cancer medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Prognostic factors in early-stage lung adenocarcinoma: a multicenter study prognostic markers in early lung adenocarcinoma.Journal of cardiothoracic surgery · 2026Article
- Predictive value of the systemic immune-inflammation index and geriatric nutritional risk index on the efficacy of immunotherapy and survival prognosis in advanced non-small cell lung cancer: a retrospective study.American journal of cancer research · 2026Article
- The Prognostic Value of Nutritional and Immune Indices for Stage IB Non-Small Cell Lung Cancer Patients: Insights From a Retrospective Cohort Study.Cancer medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundPostoperative recurrence is a critical factor affecting the prognosis of stage IB non-small cell lung cancer (NSCLC). We aimed to evaluate the prognostic value of Nutritional and Immune Indices (NII) for postoperative recurrence among IB NSCLC patients.
methodsClinical data of patients with pathological stage IB NSCLC who underwent surgical resection were collected. Cut-off values for NII were calculated using ROC curves, and patients were grouped accordingly. Univariable and multivariable logistic regression analyses were conducted to identify the association between NII and prognosis. A predictive model and corresponding nomogram were developed based on the identified risk factors. The model's performance was evaluated using the AUC and C-index. Additionally, interactions between NII and tumor marker indices were assessed, and recurrence-free survival (RFS) was analyzed using the Cox proportional hazards model.
resultsA total of 918 patients were included in this study. The results showed that patients with higher preoperative PNI or lower SII, PLR, and MLR had better RFS. For postoperative NII, patients with a higher postoperative PNI or lower PLR demonstrated better RFS. Preoperative PNI (HR = 0.920 [0.910, 0.940], p < 0.0001), postoperative MLR (HR = 1.428 [1.015, 2.010], p = 0.041) and △ (post-pre) PNI (HR = 1.018 [1.002, 1.034], p = 0.031) were identified as independent prognostic factors for postoperative recurrence in stage IB NSCLC. The nomogram model indicated that preoperative PNI was the optimal predictor for postoperative recurrence, achieving the highest C-index (0.658). Additionally, the interaction between preoperative PNI and NSE emerged as an independent prognostic factor for RFS in stage IB NSCLC patients, with a HR of 1.176 (95% CI: 1.159-1.200, p = 0.004).
conclusionsThis study underscores the value of an NII-based prognostic strategy, with preoperative PNI emerging as a particularly reliable indicator of postoperative recurrence risk in stage IB NSCLC patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.